In this issue of Neuron, Todd et al. (2013) reveal that noncanonical repeat associated non-AUG (RAN) translation occurs on nonexpanded (CGG)30-50 and premutation (CGG)59-160 repeats, associated with the FMR1 gene, suggesting that the polyglycine and polyalanine products might have natural and pathogenic roles.
''Well, in our country,'' said Alice, still panting a little, ''you'd generally get to somewhere else-if you run very fast for a long time, as we've been doing.'' ''A slow sort of country!'' said the Queen. ''Now, here, you see, it takes all the running you can do, to keep in the same place. If you want to get somewhere else, you must run at least twice as fast as that!'' -Lewis Carroll,
Through the Looking-Glass
Typically, DNA is transcribed to make an RNA, which is translated to make a protein. This translation almost always requires a signal that says, ''Translation begins here.'' This signal is an ATG motif. Moreover, typically one RNA encodes only one protein. In this issue of Neuron, Todd et al. (2013) reveal that the noncanonical process of repeat associated non-AUG (RAN) translation occurs on the CGG repeat tract present in the 5 0 UTR of FMR1. Expanded CGG repeats in FMR1 have been associated with three diseases including fragile X mental retardation type A (FRAXA), fragile X-associated premature ovarian insufficiency (FXPOI), and fragile X-associated tremor ataxia syndrome (FXTAS) (Oostra and Willemsen, 2009; Ló pez Castel et al., 2010) (Figure 1) . In unaffected individuals, the repeat is (CGG)6-52, in premutation individuals it is (CGG)59-200, and in FRAXA individuals it is (CGG)230-2,000 and aberrantly methylated at CpG sites coincident with loss of transcription and FMRP protein. Individuals with premutation lengths show increased levels of the FMR1 transcript and the CCG-containing FMR4 transcript from the strand complementary to FMR1 (Pearson et al., 2005; Oostra and Willemsen, 2009; Ló pez Castel et al., 2010 ) and can present with FXTAS or FXPOI, both of which are thought to be caused by toxic RNAs, protein binding, and sequestration, similar to myotonic dystrophy (Jin et al., 2003; Lu et al., 2012) . The findings of Todd et al. (2013) now reveal a novel pathogenic path for FMR1-related diseases.
RAN translation was recently demonstrated by the Ranum laboratory to be a novel form of translation in which there is an absence of an initiating AUG motif and initiation begins within all reading frames of an expanded (CAG)N repeat (Zu et al., 2011; Pearson, 2011) . Such events occurred in tissues of myotonic dystrophy type 1 (DM1) and spinocerebellar ataxia type 8 (SCA8) patients. Similar findings were recently reported for the C9orf72 (GGGGCC)N repeat in tissues of amyotrophic lateral sclerosis and frontotemoral dementia patients, yielding a series of dipeptide repeats (Mori et al., 2013; Ash et al., 2013) . The excitement of this newly discovered RAN translation has kept many scientists running, much as Alice did to keep up with the Queen in Lewis Carroll's Through the Looking-Glass. Todd et al. (2013) now demonstrate similar but not identical phenomena at the FMR1 CGG tract, whereby translation of the repeat occurred in the .C GGC GGC GG. or the .CG GCG GCG G. reading frames, yielding peptides of polyglycine or polyalanine. Polyarginine from the .CGG CGG CGG. reading frame was undetectable.
Functions and Pathogenesis of CGG RAN Translation
What is the role, if any, of RAN-translated products in pathogenesis and can this be distinguished from the pathogenic contribution of the CGG RNA? Separating the individual pathogenic contributions of the expanded RNA from that of RANtranslated peptides is a tough challenge, as expression of one without the other is limited by the codons encoding the homopolymers polyGly, polyAla, and polyArg, all of whose codons are redundant enough to have some repetitive nature. Identification of a factor required for RAN translation that is not required for RNA toxicity would ideally separate the contributions of each. Todd et al. (2013) show that transfection of a CGG repeat into human cells reduced cell viability that depended upon both repeat length and translation levels. In Drosophila, RAN translation of an expanded CGG RNA caused retinal degeneration. A polyGly-mediated effect was supported by enhancing or suppressing protein quality control pathways, which modulated retinal degeneration in (CGG)90 GFP-expressing flies. Thus, both toxic CGG RNA and toxic RAN proteins may contribute to disease pathogenesis. An interesting clue came from the analysis of two mouse models of FXTAS with slightly different constructs. One line, in which premutation CGG repeats integrated into the 5 0 UTR of the mouse fmr1, showed more polyGly inclusions. High levels of inclusions were present in the CNS, whereas inclusions were less frequent in a second knockin mouse that had retained a TAA stop codon just 5 0 of the integrated CGG tract, which is predicted to reduce RAN translation.
This stop codon was not present in the former mouse model. Since nuclear inclusions containing RAN-translated products were only evident in human FXTAS brains and not controls without CGG expansions, Todd et al. (2013) propose that, although RAN translation occurs in both cases, only the expanded CGG repeat leads to protein aggregation and inclusion formation. Identifying agematched asymptomatic individuals positive for premutation lengths but negative for RAN-peptide inclusions would further support the proposal of Todd et al. (2013) Table: RAN-translatable disease-associated genes and rare fragile sites whose expanded repeats may undergo RAN translation. might be the reason that CGG repeats were evolutionarily retained, even though they can be unstable and lead to disease. Second, what is the clinical effect when RAN-translation products are lost? Fragile X syndrome has long been thought to be due to a loss of the FMRP protein, mediated by loss of FMR1 transcription, which would also lead to loss of RAN-translation products. A unique female hemizygous for the FRAXA locus due to a large deletion encompassing FMR1 of one X chromosome and on the other X chromosome a microdeletion in FMR1 including all CGG repeats plus some flanking sequences, leaving transcription and translation start sites intact, displayed FMRP expression and a non-FRAXA presentation (Grønskov et al., 1997) . This individual would be devoid of FMR1 RAN-translation products. Whether the other symptoms of the patient (hearing problems and some deficits in perceptual spatial skills) were the result of the loss of FMR1 RAN-translation products or the very large deletion on the other X chromosome is not known. A FRAXA individual without CGG expansions but having an FMRP-inactivating point mutation, I304N, that still produces a (CGG)25-containing mRNA and presumably RAN-translation products, argues that there is little phenotypic contribution of the loss of RAN translation to the typical FRAXA presentation (Oostra and Willemsen, 2009; Pearson et al., 2005) . The natural functions of RAN-translation products deserve attention (Pearson, 2011 ).
Mechanism(s) of CGG RAN Translation
Using Drosophila, CGG mouse models, human cell lines, and patient tissues, Todd et al. (2013) observed RAN translation on both nonexpanded and diseaseassociated premutation CGG lengths in two of the three possible reading frames (GGC, polyGly and GCG, polyAla) involving distinct RAN-translation mechanisms for each frame. RAN translation leading to polyGly required an upstream AUG-like codon (such as GUG) and was sensitive to stop codons. PolyAla formation arose independent of AUG-like codons, was insensitive to stop codons, and was repeat length dependent. Thus, there are multiple mechanisms governing CGG RAN translation. Placement of a stop codon at À12 bp, but not at À21 bp, upstream of the CGG blocked RAN translation of polyGly, suggesting that RAN translation initiates between 21 and 12 bases 5 0 of the CGG repeat (Figure 1) . Interestingly, this same region of the FMR1 transcript had previously been identified to function as an internal ribosome entry site (IRES) and a site of ribosome pausing (Chiang et al., 2001 ). Similar to the reduced translation of FMRP from the premutation FMR1 CGG repeat compared to the nonexpanded sizes (Pearson et al., 2005; Oostra and Willemsen, 2009) , RAN translation in the polyGly frame may also be decreased with longer tracts (Todd et al., 2013) .
RAN translation of (CAG)N repeats required the formation of an intrastrand hairpin in the r(CAG)n RNA (Zu et al., 2011) , where RNA structure may impact initiation of RAN translation (Pearson, 2011) . FMR1 r(CGG)19-47 repeats were shown to form hairpins, complex multibranched or G-quadruplex structures (Napierala et al., 2005; Khateb et al., 2007) . Interestingly, the C9orf72 repeat, which also undergoes RAN translation (Mori et al., 2013; Ash et al., 2013) , was recently demonstrated to form G-quadruplexes (Reddy et al., 2013 ). The precise RNA structures and contexts (AUG-like motifs) involved in RAN translation of each repeat sequence, and possibly each reading frame, needs to be elucidated.
Where Else Might CGG RAN Translation Occur? Presumably, CGG-mediated RAN translation and the production of toxic polypeptides/inclusions may form wherever an expanded CGG repeat-containing transcript is produced (Figure 1) . The clinical presentation of FMR1 mutations is modulated by CGG tract length and aberrant CpG methylation. FRAXA patients exhibit nearly complete methylation of their expanded CGG tract, whereas rare individuals classified as ''high-functioning'' males or ''methylation mosaics'' possess unmethylated CGG repeats expanded to disease lengths and display FMR1 transcription and FMRP protein and are not affected (Pearson et al., 2005) . Albeit, males with fully expanded and methylated repeats do show some FMR1 transcript (Pearson et al., 2005; Oostra and Willemsen, 2009 ). Furthermore, unmethylated premutation (CGG)59-230 lengths, which are both transcribed and translated to FMRP, exist in the testes and sperm of males with full-mutation FRAXA, even though all other tissues display methylated disease-length alleles of (CGG)230-2,000 (Pearson et al., 2005) . In all of the above instances, the FMR1 and FMR4 transcripts with fully expanded or premutant CGG and CCG tracts may be templates for RAN translation and their potentially toxic products. Other fragile site genes, each associated with expanded CGG repeats and their CCG-containing antisense transcripts, may also undergo RAN translation (Figure 1) , as might any of the diseaseassociated expanded CAG/CTG repeats (Pearson, 2011) .
Does RAN translation occur in all premutations, FXPOI tissues, high-functioning methylation mosaics with fully expanded CGG repeats, or is it limited to FXTAS patients (Figure 1) ? Both unmethylated full mutation and premutation alleles show increased FMR1 transcript levels (Pearson et al., 2005; Oostra and Willemsen, 2009 ). Might RAN translation of the CGG tract be sensitive to repeat length, in that premutation expansions associated with FXTAS, but not fully expanded (CGG) 230-2,000 tracts, are susceptible to this phenomenon? Might the very large CGG tracts be recalcitrant to RAN translation, as premutation lengths are recalcitrant to FMRP translation (Pearson et al., 2005; Oostra and Willemsen, 2009)? That RAN translation occurs on CGG repeats of nonexpanded and premutation length transcripts broadens our understanding of both the naturally occurring FMR1 gene products as well as the potential toxic entities that may be involved in FXTAS, FXPOI, and FRAXA. This adds FMR1 to the growing list of disease-associated repeats that undergo RAN translation and those that might be (Figure 1) , with some evidence of a pathogenic role, and may be common to the 40 repeat-associated diseases.
In this issue of Neuron, Fö ldy et al. (2013) report that endocannabinoid-mediated signaling at inhibitory synapses is dysregulated in mouse models of autism-associated Neuroligin-3 mutations. These findings carry implications regarding the pathophysiology of autism spectrum disorders and the development of treatment strategies.
The correct wiring of the brain during development is an extremely complex biological process, during which a staggering number of synapses with often very diverse characteristics have to be formed and maintained in a precise and delicate balance. Not surprisingly, therefore, numerous neurodevelopmental and psychiatric diseases appear to be disorders of aberrant synaptogenesis and synapse function, or ''synaptopathies.'' Particularly in the context of autism spectrum disorders (ASDs), an evergrowing number of mutations in genes encoding synaptic proteins have been identified in affected individuals (Murdoch and State, 2013) , and major research efforts are currently focusing on strategies to transform this knowledge base into viable treatment strategies.
However, the corresponding challenges are substantial. For example, very little is known about the role of ASDrelated synaptic proteins in vivo, e.g., in neuronal circuits that control autismrelevant behavior. Second, many known ASD-related proteins are structural proteins with adhesion or scaffold functions and therefore poor targets for pharmacological intervention with small molecule drugs. Third, many ASD-related mutations lead to a loss of the corresponding protein so that no target for pharmacological intervention remains. Finally, each individual ASD-related mutation is rare, with the vast majority accounting for less than 1% of affected individuals each. In view of these difficulties, the focus in the field of ASD biology has shifted toward the identification of cellular protein-protein interactions or signaling pathways that are common to the various ASDrelated proteins and therefore expected to be perturbed by a wide range of ASD-related mutations-with the hope that such pathways may represent more promising treatment targets than the ASD-linked proteins discovered so far.
One of the synaptic proteins associated with ASDs is Neuroligin-3 (NLGN3), a member of the Neuroligin family of postsynaptic cell adhesion molecules that interact with presynaptic Neurexins to control synapse development and function. Two distinct mutations in NLGN3 have been linked to ASDs, a point mutation resulting in an R451C substitution in the Neurexin-binding domain (Jamain et al., 2003) and a deletion of the NLGN3 gene (Sanders et al., 2011) . Studies on the respective mouse models, a Nlgn3 R451C knockin (KI) and a Nlgn3 knockout (KO), showed that both mutations cause ASD-related behavioral phenotypes (Radyushkin et al., 2009; Tabuchi et al., 2007) but have strikingly different effects on synapse and network function, with the Nlgn3 R451C mutation resulting in a gain-of-function phenotype that is
